This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ASM journals
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Russell, B.
Right arrow Articles by Price, R. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Russell, B.
Right arrow Articles by Price, R. N.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 2008, p. 1040-1045, Vol. 52, No. 3
0066-4804/08/$08.00+0     doi:10.1128/AAC.01334-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Determinants of In Vitro Drug Susceptibility Testing of Plasmodium vivax{triangledown}

B. Russell,1 F. Chalfein,2 B. Prasetyorini,3 E. Kenangalem,2,4 K. Piera,1 R. Suwanarusk,1 A. Brockman,1 P. Prayoga,2 P. Sugiarto,5 Q. Cheng,6 E. Tjitra,3 N. M. Anstey,1 and R. N. Price1,7*

International Health Program, Infectious Diseases Division, Menzies School of Health Research and Charles Darwin University, Darwin, Australia,1 Menzies School of Health Research—National Institute of Health Research and Development Malaria Research Program, Timika, Indonesia,2 National Institute of Health Research and Development, Ministry of Health, Jakarta, Indonesia,3 District Ministry of Health, Timika, Papua, Indonesia,4 Mitra Masyarakat Hospital, Timika, Indonesia,5 Department of Drug Resistance and Diagnostics, Australian Army Malaria Institute, Brisbane, Australia,6 Centre for Vaccinology and Tropical Medicine, Nuffield Department of Clinical Medicine, John Radcliffe Hospital, Oxford, United Kingdom7

Received 16 October 2007/ Returned for modification 1 December 2007/ Accepted 24 December 2007

In Papua, Indonesia, the antimalarial susceptibility of Plasmodium vivax (n = 216) and P. falciparum (n = 277) was assessed using a modified schizont maturation assay for chloroquine, amodiaquine, artesunate, lumefantrine, mefloquine, and piperaquine. The most effective antimalarial against P. vivax and P. falciparum was artesunate, with geometric mean 50% inhibitory concentrations (IC50s) (95% confidence intervals [CI]) of 1.31 nM (1.07 to 1.59) and 0.64 nM (0.53 to 0.79), respectively. In contrast, the geometric mean chloroquine IC50 for P. vivax was 295 nM (227 to 384) compared to only 47.4 nM (42.2 to 53.3) for P. falciparum. Two factors were found to significantly influence the in vitro drug response of P. vivax: the initial stage of the parasite and the duration of the assay. Isolates of P. vivax initially at the trophozoite stage had significantly higher chloroquine IC50s (478 nM [95% CI, 316 to 722]) than those initially at the ring stage (84.7 nM [95% CI, 45.7 to 157]; P < 0.001). Synchronous isolates of P. vivax and P. falciparum which reached the target of 40% schizonts in the control wells within 30 h had significantly higher geometric mean chloroquine IC50s (435 nM [95% CI, 169 to 1,118] and 55.9 nM [95% CI, 48 to 64.9], respectively) than isolates that took more than 30 h (39.9 nM [14.6 to 110.4] and 36.9 nM [31.2 to 43.7]; P < 0.005). The results demonstrate the marked stage-specific activity of chloroquine with P. vivax and suggest that susceptibility to chloroquine may be associated with variable growth rates. These findings have important implications for the phenotypic and downstream genetic characterization of P. vivax.

* Corresponding author. Mailing address: Menzies School of Health Research, P.O. Box 41096, Casuarina, Darwin, NT 0811 Australia. Phone: 61 8 8922 8197. Fax: 61 8 8922 8429. E-mail: rnp{at}menzies.edu.au

{triangledown} Published ahead of print on 7 January 2008.

Antimicrobial Agents and Chemotherapy, March 2008, p. 1040-1045, Vol. 52, No. 3
0066-4804/08/$08.00+0     doi:10.1128/AAC.01334-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Baird, J. K. (2009). Resistance to Therapies for Infection by Plasmodium vivax. Clin. Microbiol. Rev. 22: 508-534 [Abstract] [Full Text]  
  • Hasugian, A. R., Tjitra, E., Ratcliff, A., Siswantoro, H., Kenangalem, E., Wuwung, R. M., Purba, H. L. E., Piera, K. A., Chalfien, F., Marfurt, J., Penttinen, P. M., Russell, B., Anstey, N. M., Price, R. N. (2009). In Vivo and In Vitro Efficacy of Amodiaquine Monotherapy for Treatment of Infection by Chloroquine-Resistant Plasmodium vivax. Antimicrob. Agents Chemother. 53: 1094-1099 [Abstract] [Full Text]  
  • Baird, J. K. (2008). Real-World Therapies and the Problem of Vivax Malaria. NEJM 359: 2601-2603 [Full Text]  
  • Pukrittayakamee, S., Imwong, M., Singhasivanon, P., Stepniewska, K., Day, N. J., White, N. J. (2008). Effects of Different Antimalarial Drugs on Gametocyte Carriage in P. Vivax Malaria. Am J Trop Med Hyg 79: 378-384 [Abstract] [Full Text]  
  • Lek-Uthai, U., Suwanarusk, R., Ruengweerayut, R., Skinner-Adams, T. S., Nosten, F., Gardiner, D. L., Boonma, P., Piera, K. A., Andrews, K. T., MacHunter, B., McCarthy, J. S., Anstey, N. M., Price, R. N., Russell, B. (2008). Stronger Activity of Human Immunodeficiency Virus Type 1 Protease Inhibitors against Clinical Isolates of Plasmodium vivax than against Those of P. falciparum. Antimicrob. Agents Chemother. 52: 2435-2441 [Abstract] [Full Text]  


Copyright © 2010 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»